Article Text

Download PDFPDF
Letter
Tenofovir may be superior to entecavir for preventing hepatocellular carcinoma and mortality in individuals chronically infected with HBV: a meta-analysis
  1. Yu-Xian Teng,
  2. Min-Jun Li,
  3. Bang-De Xiang,
  4. Jian-Hong Zhong
  1. Hepatobiliary Surgery Department, Guangxi Medical University Cancer Hospital, Nanning, China
  1. Correspondence to Dr Jian-Hong Zhong, Hepatobiliary Surgery Department, Guangxi Medical University Cancer Hospital, Nanning 530021, China; zhongjianhong66{at}163.com

Statistics from Altmetric.com

Many studies have demonstrated that monotherapy with tenofovir disoproxil fumarate (TDF) or entecavir (ETV) can reduce the risk of liver complications in individuals chronically infected with HBV (CHB). Unclear is whether one monotherapy is more effective than the other at preventing these outcomes. In a recent issue of this journal, Lee and coworkers1 reported data from a large population of treatment-naive CHB patients in which risk of hepatocellular carcinoma (HCC), all-cause mortality or liver transplantation was similar with either monotherapy. Similar results were observed in subgroups of patients with chronic hepatitis or cirrhosis. While this study involved more than 7000 South Korean patients who were enrolled during more than a decade and whose virological and biochemical data over several years were analysed, its findings must be treated with caution because the two groups differed substantially in median …

View Full Text

Footnotes

  • Contributors J-HZ conceived the study, and J-HZ and B-DX designed the search strategy and statistical analysis. J-HZ, Y-XT and M-JL collected the data. J-HZ drafted and revised the manuscript. J-HZ is guarantor of the study. All authors had full access to all the data in the study and can take responsibility for data integrity and accuracy of the data analysis. All authors approved the final version of the article.

  • Funding This work was supported by the Graduate Course Construction Project of Guangxi Medical University (YJSA2017014), the Foundation Ability Enhancement Project for Young Teachers in Guangxi Universities (2018KY0122) and ‘Guangxi BaGui Scholars’ special fund.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Ethics approval This was a comprehensive review, and all the included studies have obtained this approval from their own institutions.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.